A clinical evaluation of serological diagnosis for pancreatic cancer

Table 3 The relationship between the tests of tumor markers and the location, size or differentiation of pancreatic cancer

Groups	Location			Size			Differentiation
	Head	Body or tail	Entire	< 5.0 cm	5 cm-9.0 cm	< 9.0 cm	Well & moderate	Poor & un-differentiated
POA	9/11 (81.82)	3/6 (50.00)	1/3 (33.33)	4/8 (50.00)	8/10 (80.00)	1/2 (50.00)
mPOA	22/27 (81.48)	5/9 (55.56)	2/3 (66.67)	5/5 (100.00)	14/19 (73.68)	10/15 (66.67)	10/10 (100.00)	9/13 (69.23)
PCAAc	17/22 (77.27)	4/9 (44.44)	1/2 (50.55)	3/4 (75.00)	9/13 (69.23)	3/6 (50.00)	5/5 (100.00)	2/4 (50.00)
PaA	16/22 (72.73)	10/11 (90.91)	2/2 (100.00)	4/4 (100.00)	12/15 (80.00)	6/10 (60.00)	8/8 (100.00)	4/5 (80.00)
E1	14/17 (82.35)	2/6 (33.33)	2/3 (66.67)	6/8 (75.00)	4/10 (40.00)	1/2 (50.00)	3/6 (50.00)	2/4 (50.00)
HPE1	35/41 (85.37)	20/35 (57.14)	7/17 (41.18)	40/51 (78.43)	15/25 (60.00)	7/17 (41.18)	43/60 (71.67)	19/33 (57.58)
GPDA	14/22 (63.64)	0/9 (0.00)	0/2 (0.00)	8/17 (47.06)	3/7 (42.86)	3/7 (42.86)	4/7 (57.14)	1/4 (25.00)
RNase	31/41 (75.61)	24/35 (68.23)	15/17 (88.23)	20/29 (68.96)	19/25 (76.00)	15/17 (88.24)	46/ 60 (76.67)	24/33 (72.72)
CA19-9	10/17 (58.82)	6/8 (75.00)	6/6 (100.00)	7/15 (46.67)	9/12 (75.00)	4/4 (100.00)	8/9 (88.89)	8/8 (100.00)